AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 191 min read$PHIO

Bitterman Robert J purchased $11K of PHIO

Bitterman Robert J (Chairman, Pres. & CEO) purchased 10,000 shares of Phio Pharmaceuticals Corp. (PHIO) at $1.06 on 2026-08-18.

Original reporting
SEC EDGAR · Bitterman Robert J
Published Aug 19, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 8:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PHIO
Neutral
high confidence
Mentioned
$PHIO
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHIONeutralLow
01

Why it matters

The purchase modestly raises insider ownership, offering a mild bullish cue.

02

Market read

Limited impact; primarily of interest to shareholders tracking insider activity.

03

What to watch

Potential upcoming clinical data could amplify the significance of insider confidence.

Relevance 4/10Novelty 4/10Timing: post‑market 2026‑08‑18

Background

Form 4 filings disclose insider trades; investors watch for material buying by executives.

Company-level read

Ticker impact

$PHIONeutralHigh confidence
Context

Chairman Robert J. Bitterman bought 10,000 shares for $10,600, increasing his stake to 431,421 shares.

Expected impact

Minimal short‑term move; may support slight upside bias.

Evidence & confidence

The transaction size is modest relative to market cap; insider buying is a positive signal but unlikely to move the stock materially.

Market effects

Sector

None; biotech sector unchanged.

Regional

None; US‑listed micro‑cap only.

Global

None

Counterpoint

What could challenge this read

Insider purchase could be routine portfolio rebalancing, not a strong buy signal.

Key entities

  • Company
    Phio Pharmaceuticals Corp.

    Biotech firm developing therapies for rare diseases.

  • Executive
    Robert J. Bitterman

    Chairman, President & CEO of Phio.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PHIO insider trading history →

Related articles

SEP 14
$PHIOMedAI 8/10

Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma

Phio Pharmaceuticals (PHIO) submitted a meeting request and briefing package to the FDA for PH-762, its lead clinical compound for cutaneous squamous cell carcinoma. The submission follows the completion of a Phase 1b trial and outlines plans for a Phase 2b study. The company expects to complete final activities for the next clinical phase by Q1 2027.

insidermonkey.com2 min
AUG 6
$PHIOMedAI 8/10

Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

Phio Pharmaceuticals (NASDAQ: PHIO) reported Q2 2026 results for the quarter ended June 30, 2026 and updated its PH-762 siRNA program. Cash fell to $13.0M from $21.0M at Dec. 31, 2025. R&D rose to $3.1M and net loss widened to $4.1M. PH-762 Phase 1b (22 patients) completed in March; FDA documentation is being prepared and an FDA meeting is planned for Q3 2026. The company also launched a $6.36M ATM equity program.

finanznachrichten.de7 min
AUG 6
$PHIOMed

Phio Pharmaceuticals Corp. (PHIO): Results of Operations and Financial Condition

Phio Pharmaceuticals Corp. (PHIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update Strategic milestone advancements for lead clinical candidate PH-762 Initiation of commercial scale API, long term non-clinical toxicology, completion of Phase 1b pharmacology, and

SEC EDGAR 8-K6 min